Nummi, Päivi https://orcid.org/0000-0002-8058-0783
Taira, Aurora https://orcid.org/0000-0002-1179-8500
Ravantti, Janne https://orcid.org/0000-0002-8578-7230
Norri, Tuukka https://orcid.org/0000-0002-8276-0585
Välimäki, Niko https://orcid.org/0000-0001-9200-9560
Lepistö, Anna
Renkonen-Sinisalo, Laura
Koskensalo, Selja https://orcid.org/0000-0001-6959-8715
Seppälä, Toni T. https://orcid.org/0000-0002-4940-3498
Ristimäki, Ari https://orcid.org/0000-0002-5373-9234
Tahkola, Kyösti https://orcid.org/0000-0002-1626-5690
Mattila, Anne
Böhm, Jan
Mecklin, Jukka-Pekka
Siili, Emma
Pasanen, Annukka
Heikinheimo, Oskari https://orcid.org/0000-0002-8671-130X
Bützow, Ralf https://orcid.org/0000-0003-4366-5099
Karhu, Auli https://orcid.org/0000-0002-7927-0796
Aaltonen, Lauri A. https://orcid.org/0000-0001-6839-4286
Palin, Kimmo https://orcid.org/0000-0002-4621-6128
Cajuso, Tatiana https://orcid.org/0000-0002-6354-5572
Funding for this research was provided by:
Syöpäsäätiö (230068, 200071)
Jane ja Aatos Erkon Säätiö (220001)
Article History
Received: 15 July 2025
Accepted: 29 January 2026
First Online: 12 February 2026
Competing interests
: The authors declare the following competing interests: T.T.S. reports consultation fees from Mehiläinen, Nouscom, Orion Pharma, Amgen, and Tillots Pharma, and a position in the Clinical Advisory Board and as a minor shareholder of Lynsight Ltd. The other authors declare no competing interests.